Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

NovaBay Pharmaceuticals (NBY) Debt Ratio (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Debt Ratio for 8 consecutive years, with 0.04 as the latest value for Q3 2025.

  • On a quarterly basis, Debt Ratio rose 224.83% to 0.04 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.04, a 224.83% increase, with the full-year FY2024 number at 0.02, changed N/A from a year prior.
  • Debt Ratio was 0.04 for Q3 2025 at NovaBay Pharmaceuticals, up from 0.02 in the prior quarter.
  • In the past five years, Debt Ratio ranged from a high of 0.18 in Q1 2024 to a low of 0.0 in Q4 2021.
  • A 4-year average of 0.06 and a median of 0.03 in 2024 define the central range for Debt Ratio.
  • Biggest YoY gain for Debt Ratio was 224.83% in 2025; the steepest drop was 95.32% in 2025.
  • NovaBay Pharmaceuticals' Debt Ratio stood at 0.0 in 2021, then surged by 2156.61% to 0.1 in 2023, then plummeted by 80.78% to 0.02 in 2024, then surged by 125.02% to 0.04 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Debt Ratio are 0.04 (Q3 2025), 0.02 (Q2 2025), and 0.01 (Q1 2025).